Artivion Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Morning, everyone. For everyone listening, my name is John McAulay. I am one of the medical technology analysts here at Stifel. It is my pleasure to welcome Artivion to this year's Stifel Healthcare Conference. We have the company's Chairman, President, CEO, Pat Mackin, along with Lance Berry, the COO and CFO. Thank you both for being here. I want to start off today on the third quarter results and then the updated 2026 guidance you provided just last week, as well as some of the earlier 2027 directional comments you made before we get into the product-specific stuff. First, starting off on the fourth quarter, as I look at the rest of your guidance, the midpoint of the range actually contemplates a sequential revenue step-down in the fourth quarter, which is pretty unusual based on your typical seasonality.
I just thought we could start off with talking about what is actually implied in that guidance and if there are any reasons to think it might be better.
I think at a high level, if you step back and look at the second half, we essentially, I would say, reiterated the midpoint of our second-half guidance, is essentially what we did. There is some timing with our preservation services business was better than anticipated in Q3, which we think is really just timing between Q3 and Q4. If you look at the second half in total, it is basically in line with what we expected. The preservation services, if you think about that really has no implication on going forward beyond Q4. That is really just a timing thing between Q3 and Q4. Overall, that business is probably going to come in a little ahead of expectations for the year.
I would tell people really not to look at the second half more in total than trying to parse out Q3 versus Q4 due to the timing thing. Also just be aware if you are looking at the raw dollars of the guide, that currency was pretty neutral in Q3, but is a healthy percentage point headwind in Q4. Those would just be the two things I would tell people to keep in mind as you look at that. Really, you have to look through the numbers a little bit, but in total, the second half is kind of shaping up the way we expected it to.
Got it. You also talked about on the call that next year, the PerClot revenues that you've been generating as you produce it for Baxter are going to end. You indicated that it's about a 2-point negative impact on revenue growth, 4 points to EBITDA. in a given year for you guys, I would think about you as sort of a 10% top-line grower, 15%-20% adjusted EBITDA. Purely in a vacuum, the PerClot impact would imply something like 8% revenue growth, low double digit to mid-teens adjusted EBITDA for next year. At a high level, is that sort of the right way we should be thinking about things?
I'll let Lance comment on some of the numbers, but let me just take a step back for a second. We sold PerClot, this is a hemostat, we sold it to Baxter 5 years ago. We've been operating under a transition services agreement. If we'd run that and discontinued ops, we wouldn't be talking about it right now. We probably should have done that. It's a non-strategic asset. The transition service agreement is going away, right? At the higher level is, organically, we are committed to growing double-digit top line and twice as fast on the bottom line. This PerClot thing is, it's getting a lot of attention, and I understand it's like, as reported, but I'll let Lance comment on the financial part of it. It's not something we even really talk about in the company.
Yeah. I guess, thanks for the background, Pat, because it was pretty long time ago that we actually sold this. It's just taken quite a while for Baxter to get to the point where they could ready to transition and take over the manufacturing. They had numerous regulatory approvals they had to get for that, and we really only very recently got confirmation that, yes, they're ready to take it over and it's going to end, which is, then we can be clear with everyone that it's going to go away. If you look at, John, you talked about more of that 8% top line and probably like mid-teens-ish kind of EBITDA growth is where the consensus is now factoring that in.
As Pat said, if you look at that on an organic basis, that's right at the 10% and 20% that we're telling people in general in any given year, that's what we're shooting for, is trying to do that or better. I think really that's the way to think about it. On an organic basis, that's consistent with what we've kind of told you in any given year about this time of year, about the next year, and that's what we're telling you again.
That's helpful. The 2027 PerClot impact isn't taking place in a vacuum. You also have a product launch next year, NEXUS. You've talked about a $100 million U.S. addressable market. Could what you gain from NEXUS potentially offset PerClot?
Yeah, again, we're just giving some directional comments on 2027. We'll have a lot more information in February. We'll actually know a lot more about NEXUS in February. We'll be a good month into the actual launch at that point and have done a lot of various, probably maybe multiple trainings. I think we'll have more information at that point. Right now, we're telling people, "Hey, let's just stick with the high level, more organic 10% and 20% as a better starting point, and we'll have more information." We got quite a bit of time between now and then to gather a lot more information and being a lot more intelligent on impact of 2027 for NEXUS and lots of other things too.
Got it. Switching to gross margins, just again, as I look ahead for the business here, it seems like your mix is moving towards higher margin products. You've got PerClot coming off the books. You've got the tissue business growing below the other assets. In general, should we be thinking about this business as one with gross margin expansion in 2027 as opposed to 2026? It seems like that's the directionally things should be trending.
Directionally, yes. We can get into February, we'll get more into magnitude, but there are definitely some tailwinds for gross margin, all the things that you mentioned.
Mm-hmm. I want to shift gears now to AMDS, starting off with utilization reorders. You talked about it on the third quarter call, higher utilization or more reorders than you saw in the second quarter. Can you just give us a bit more color about what you are seeing from sort of the top sites in terms of utilization, growth, and how that might be an indicator for other sites working up the curve?
Yeah. Just to remind folks, right, there is two sources of revenue for AMDS. There is the starter sets, which you need to buy four. We have four sizes. You need to buy all four sizes to start your account, and then there is reorders. So there is kind of the two buckets. What we had said was once we get the PMA, we thought it would help on the reorders just because you no longer have to do the IRB kind of constraining things that they had in some of the centers. We have definitely seen, I made a comment in October, we have seen a pretty significant acceleration of implants, which ultimately is the metric where is most important for the company, looking at AMDS and its adoption. As you can imagine in any launch, there is 800 centers, 400 of them do the most volume.
We are seeing various levels of adoption in each of those centers that we are in. We are not in all of those accounts as of yet, but we are definitely seeing the implants accelerating, and we expect to see that to continue.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
